Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM-EV: Oral Treprostinil in PAH
NCT01560624Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2012
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Jun 2012; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01560624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01560624.